SUMMARY OF DECISIONS FOR APPROVAL

Decisions made by: CRG	**At their meeting on: 11th July 2023**
For approval by: GMMMG	**At their meeting on: 10th August 2023**

Decisions made by: CRG (except those * which were made at GMMMG)	**11th July 2023**
Approved by: GMMMG	**10th August 2023**
Approved by: CEGC	**30th August 2023**
Approved by: Executive	**There are no decisions with a financial impact therefore all decisions were approved at CEGC.**

The NHS is legally obliged to fund and resource medicines and treatments recommended by NICE's technology appraisals. When NICE recommends a treatment 'as an option', the NHS must make sure it is available within 90 days (unless otherwise specified) of its date of publication. This means that, if a patient has a disease or condition and the doctor responsible for their care thinks that the technology is the right treatment, it should be available for use, in line with NICE's recommendations.

DECISIONS WITH A FINANCIAL OR COMMISSIONING IMPACT

Drug and indication	Rationale / criteria	Status and formulary position assigned	Notes on decision	Cost impact and commissioning / service implications	Recommendation for GMMMG
None					

DECISIONS WITHOUT A FINANCIAL OR COMMISSIONING IMPACT

Drug and indication	Rationale / criteria	Status and formulary position assigned	Notes on decision	Cost impact and commissioning / service implications	Recommendation
Fosfomycin 3g oral sachets For uncomplicated UTI in non-pregnant women	This medicine currently has a RAG status of Green (specialist advice) which was agreed in 2015 when the medicine was unlicensed and was an expensive alternative. It is now licensed and is similarly priced to a 3 day course of nitrofurantoin M/R and pivmecillinam, both of which are treatment options in this pathway	On formulary and included in the GM antimicrobial guidelines as alternative where preferred choice is unsuitable. **Change RAG from Green (specialist advice) to Green**		At current prices (drug Tariff May 2023) a single dose of Fosfomycin is £4.86 compared to Nitrofurantoin M/R 100mg twice daily for 3 days, £4.07, trimethoprim 200mg twice daily for 3 days, £0.54 and pivmecillinam 200mg three times daily for 3 days, £5.40 This recommendation is likely to be cost neutral because fosfomycin remains an alternative option to be prescribed if preferred treatments are not suitable. There are no expected commissioning or service implications from this decision	Approve the change in RAG status
GM antimicrobial guidance 4.2b GM Antimicrobial guidel	The update to this guidance includes information on: • Drug Safety Update April 2023 regarding Nitrofurantoin. • Otinova Ear Spray for acute otitis externa was considered as an addition but determined not to add as it is not a licensed drug rather a device, nor supported by robust evidence. • Acne Vulgaris NICE NG198 update.	All medicines on formulary		None	Note the amendment and approve the updated guidance
GM Hypertension pathway GM Hypertension Pathway V9.2 Final.pd	Developed by a cross-sector multidisciplinary task and finish group with the SCN and approved by CRG, this guidance aims to standardise hypertension management in GM by using a pragmatic approach to treatment whilst adhering to NICE guidance. This guidance represents part of a wider system approach to tackling one of the ICB's priority areas of reducing CVD.	All medicines are on the formulary as Green	2 supporting documents are being prepared to describe the background and rationale for the pathway and further information about the recommended medicines.	The drugs involved are all standard drugs used within the hypertension pathway and are all part of the GMMMG formulary. These are off patent and widely available as generics. They are inexpensive and annual costs of treatment will often be less than £30 per patient per year even with dual therapy.	Approve the pathway
GMMMG ustekinumab dose escalation commissioning statement Ustekinumab in CD commisising statemer	An update to the previously approved and published commissioning position on this document was approved. There has been no change to the "not recommended for routine commissioning" position. The changes are limited to a technical review and allow for the addition 0of published phase 3b trial data on a new study which support the current position.	not recommended for routine commissioning		None. This update maintains the existing commissioning recommendations	Note the amendment and approve the updated position statement

DECISIONS FOR INFORMATION ONLY

Drug and indication	Rationale / criteria	Status and formulary position assigned	Notes on decision	Cost impact
TA880: Tezepelumab for treating severe asthma **Commissioning: NHSE** Tezepelumab as an add-on maintenance treatment is recommended as an option for severe asthma in people 12 years and over, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has not worked well enough. It is recommended only if people: • have had 3 or more exacerbations in the previous year, or • are having maintenance oral corticosteroids. • Tezepelumab is recommended only if the company provides it according to the commercial arrangement.	Not on formulary. Other monoclonal antibodies for asthma are on formulary as RED drugs in chapter 3.	Add to formulary in chapter 3.4.2 as a RED drug in this indication, with link to TA880.	For information only	Resource impact statement available NICE expect the resource impact of implementing the recommendations in England will be less than approximately £8,800 per 100,000 population. This is because the technology is a further treatment option and the overall cost of treatment will be similar to other treatment options.
TA879: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) **Commissioning: NHSE** NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	All anti-cancer drugs with a positive NICE Health Technology Appraisal are approved for use in Greater Manchester.	For info, no action.	For information only	N/A
GMMMG July minutes*	PDF GMMMG Minutes July 23.pdf	Approved for publication		
GMMMG August 23 agenda	PDF GMMMG August 2023 agenda.pdf	Approved for publication		

Regional Drug and Therapeutics Centre
16/17 Framlington Place, Newcastle upon Tyne, NE2 4AB
Tel: **0191 213 7855** Fax: **0191 261 8839** email: nuth.nyrdtc.rxsupp@nhs.net visit: https://rdtc.nhs.uk

@RDTC_Rx